Trends in Clinical Investigation for Myelodysplastic Syndromes

被引：9

作者：

Prebet, Thomas ^{[1
]}

Zeidan, Amer ^{[1
]}

机构：

[1] Yale Sch Med, Sect Hematol, Dept Internal Med, 300 Georges St,Room 786, New Haven, CT 06511 USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2016年 / 16卷

关键词：

Epigenetic; Erythropoiesis; Immunotherapy; Myelodysplasia; Trial; ACUTE MYELOID-LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; TRANSFUSION-DEPENDENT PATIENTS; INTERNATIONAL WORKING GROUP; PROGNOSTIC SCORING SYSTEM; PHASE-I; LENALIDOMIDE TREATMENT; TET2; MUTATIONS; DELETION; 5Q; RISK;

D O I：

10.1016/j.clml.2016.02.012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Myelodysplastic syndrome (MDS) paradigms have been dramatically changed over the last 10 years by major breakthroughs on both pathophysiologic and therapeutic aspects. It is currently a field of intense clinical investigation as new challenges have emerged in both low-risk and high-risk populations. In low-risk MDS, long-term control of anemia is a major issue, and second-line treatments after failure of erythropoiesis-stimulating agents are warranted. Several promising therapies are available, and there are many open questions on how to select the most adapted agent and/or sequence of agents in a specific individual. For high-risk MDS patients, improvement of frontline treatment (namely hypomethylating agents) and identification of valid treatments for relapsed/refractory patients are of paramount importance. This review attempts to define these challenges, summarize the results of the most recent and promising investigational strategies in the field, and to describe the future directions.

引用

页码：S57 / S63

页数：7

共 71 条

[41] Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic Syndromes [J].

Lyons, Roger M. ;

Cosgriff, Thomas M. ;

Modi, Sanjiv S. ;

Gersh, Robert H. ;

Hainsworth, John D. ;

Cohn, Allen L. ;

McIntyre, Heidi J. ;

Fernando, Indra J. ;

Backstrom, Jay T. ;

Beach, C. L. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (11) :1850-1856

[42] Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet [J].

Malcovati, Luca ;

Hellstrom-Lindberg, Eva ;

Bowen, David ;

Ades, Lionel ;

Cermak, Jaroslav ;

del Canizo, Consuelo ;

Della Porta, Matteo G. ;

Fenaux, Pierre ;

Gattermann, Norbert ;

Germing, Ulrich ;

Jansen, Joop H. ;

Mittelman, Moshe ;

Mufti, Ghulam ;

Platzbecker, Uwe ;

Sanz, Guillermo F. ;

Selleslag, Dominik ;

Skov-Holm, Mette ;

Stauder, Reinhard ;

Symeonidis, Argiris ;

van de Loosdrecht, Arjan A. ;

de Witte, Theo ;

Cazzola, Mario .

BLOOD, 2013, 122 (17) :2943-2964

[43] More is better: Combination therapies for myelodysplastic syndromes [J].

Ornstein, Moshe C. ;

Mukherjee, Sudipto ;

Sekeres, Mikkael A. .

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2015, 28 (01) :22-31

[44] Clinical and biological implications of driver mutations in myelodysplastic syndromes [J].

Papaemmanuil, Elli ;

Gerstung, Moritz ;

Malcovati, Luca ;

Tauro, Sudhir ;

Gundem, Gunes ;

Van Loo, Peter ;

Yoon, Chris J. ;

Ellis, Peter ;

Wedge, David C. ;

Pellagatti, Andrea ;

Shlien, Adam ;

Groves, Michael John ;

Forbes, Simon A. ;

Raine, Keiran ;

Hinton, Jon ;

Mudie, Laura J. ;

McLaren, Stuart ;

Hardy, Claire ;

Latimer, Calli ;

Della Porta, Matteo G. ;

O'Meara, Sarah ;

Ambaglio, Ilaria ;

Galli, Anna ;

Butler, Adam P. ;

Walldin, Gunilla ;

Teague, Jon W. ;

Quek, Lynn ;

Sternberg, Alex ;

Gambacorti-Passerini, Carlo ;

Cross, Nicholas C. P. ;

Green, Anthony R. ;

Boultwood, Jacqueline ;

Vyas, Paresh ;

Hellstrom-Lindberg, Eva ;

Bowen, David ;

Cazzola, Mario ;

Stratton, Michael R. ;

Campbell, Peter J. .

BLOOD, 2013, 122 (22) :3616-3627

[45] Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF:: the GFM experience [J].

Park, Sophie ;

Grabar, Sophie ;

Kelaidi, Charikleia ;

Beyne-Rauzy, Odile ;

Picard, Francoise ;

Bardet, Valerie ;

Coiteux, Valerie ;

Leroux, Genevieve ;

Lepelley, Pascale ;

Daniel, Marie-Therese ;

Cheze, Stephane ;

Mahe, Beatrice ;

Ferrant, Augustin ;

Ravoet, Christophe ;

Escoffre-Barbe, Martine ;

Ades, Lionel ;

Vey, Norbert ;

Aljassern, Lina ;

Stamatoullas, Aspasia ;

Mannone, Lionel ;

Dombret, Herve ;

Bourgeois, Keith ;

Greenberg, Peter ;

Fenaux, Pierre ;

Dreyfus, Francois .

BLOOD, 2008, 111 (02) :574-582

[46]

Platzbecker U, 2015, EHA ABSTRACT BOOK, V100, P1

[47]

Pollyea DA, 2014, 26 EORTC NCI AACR S

[48] Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905 [J].

Prebet, Thomas ;

Sun, Zhuoxin ;

Figueroa, Maria E. ;

Ketterling, Rhett ;

Melnick, Ari ;

Greenberg, Peter L. ;

Herman, James ;

Juckett, Mark ;

Smith, Mitchell R. ;

Malick, Lisa ;

Paietta, Elisabeth ;

Czader, Magdalena ;

Litzow, Mark ;

Gabrilove, Janice ;

Erba, Harry P. ;

Gore, Steven D. ;

Tallman, Martin S. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (12) :1242-+

[49] Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes [J].

Prebet, Thomas ;

Braun, Thorsten ;

Beyne-Rauzy, Odile ;

Dreyfus, Francois ;

Stammatoullas, Aspasia ;

Wattel, Eric ;

Ame, Shanti ;

Raffoux, Emmanuel ;

Delaunay, Jacques ;

Charbonnier, Aude ;

Ades, Lionel ;

Fenaux, Pierre ;

Vey, Norbert .

LEUKEMIA RESEARCH, 2014, 38 (01) :29-33

[50] Lenalidomide treatment for patients with myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure [J].

Prebet, Thomas ;

Charbonnier, Aude ;

Gelsi-Boyer, Veronique ;

Mozziconacci, Marie Joelle ;

Blaise, Didier ;

Vey, Norbert .

LEUKEMIA & LYMPHOMA, 2013, 54 (07) :1538-1540

← 1 2 3 4 5 6 7 8 →